ERBB2 and serous adenocarcinoma: In another study, HER2 3+ expression was seen in only 1 out of 53 cases of primary serous carcinoma, and HER2 amplification by CISH was not identified in 43 serous carcinomas (0/43), so the authors concluded that HER2 was not altered in ovarian serous carcinoma [35].